Eric Morgen presents how BioAge Labs is addressing metabolic diseases driven by the aging process by leveraging biomarkers of aging. He also shares updates on their leading clinical assets.

Timestamps:
[00:00:08] Biomarkers in aging clinical trials introduction
[00:01:08] How BioAge Labs tackles metabolic diseases
[00:03:15] Developing a pipeline of broad therapies, including Azelaprag harnessing the biology of human aging
[00:05:18] The BioAge Platform: Apelin signaling
[00:08:03] Biomarkers of aging to showcase Azelaprag's safety and efficacy
[00:12:10] Proteomic effects of Azelaprag

Dr. Eric Morgen is the co-founder and COO of BioAge Labs, a clinical stage biotechnology company harnessing the biology of human aging to develop new therapies for diseases. Learn more about BioAge Labs here: [ Ссылка ]

свернуть